Filing Details
- Accession Number:
- 0001214659-21-001095
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-01 21:47:25
- Reporting Period:
- 2021-01-29
- Accepted Time:
- 2021-02-01 21:47:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1576263 | Mirati Therapeutics Inc. | MRTX | Pharmaceutical Preparations (2834) | 462693615 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1761768 | E Maria Martinez | C/O Mirati Therapeutics, Inc. 9393 Towne Centre Drive, Ste 200 San Diego CA 92121 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-29 | 7,500 | $39.76 | 10,975 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-29 | 50 | $197.14 | 10,925 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 250 | $198.48 | 10,675 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 719 | $200.05 | 9,956 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 462 | $200.90 | 9,494 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 960 | $201.99 | 8,534 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 1,579 | $203.43 | 6,955 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 1,205 | $204.43 | 5,750 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 975 | $205.26 | 4,775 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 1,100 | $206.63 | 3,675 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-29 | 200 | $207.83 | 3,475 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Commonstock | Non Qualified Stock Option (right to buy) | Disposition | 2021-01-29 | 7,500 | $0.00 | 7,500 | $39.76 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
17,500 | 2028-12-05 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2020.
- This transaction was executed in multiple trades at prices ranging from $198.23 to $199.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $199.51 to $200.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $200.55 to $201.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $201.63 to $202.545. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $202.97 to $203.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $204.00 to $204.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $205.00 to $205.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $206.215 to $206.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $207.74 to $207.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant.